» Articles » PMID: 38796567

IGFBP2 Induces Podocyte Apoptosis Promoted by Mitochondrial Damage Via Integrin α5/FAK in Diabetic Kidney Disease

Overview
Journal Apoptosis
Publisher Springer
Date 2024 May 25
PMID 38796567
Authors
Affiliations
Soon will be listed here.
Abstract

Podocyte apoptosis or loss is the pivotal pathological characteristic of diabetic kidney disease (DKD). Insulin-like growth factor-binding protein 2 (IGFBP2) have a proinflammatory and proapoptotic effect on diseases. Previous studies have shown that serum IGFBP2 level significantly increased in DKD patients, but the precise mechanisms remain unclear. Here, we found that IGFBP2 levels obviously increased under a diabetic state and high glucose stimuli. Deficiency of IGFBP2 attenuated the urine protein, renal pathological injury and glomeruli hypertrophy of DKD mice induced by STZ, and knockdown or deletion of IGFBP2 alleviated podocytes apoptosis induced by high concentration of glucose or in DKD mouse. Furthermore, IGFBP2 facilitated apoptosis, which was characterized by increase in inflammation and oxidative stress, by binding with integrin α5 (ITGA5) of podocytes, and then activating the phosphorylation of focal adhesion kinase (FAK)-mediated mitochondrial injury, including membrane potential decreasing, ROS production increasing. Moreover, ITGA5 knockdown or FAK inhibition attenuated the podocyte apoptosis caused by high glucose or IGFBP2 overexpression. Taken together, these findings unveiled the insight mechanism that IGFBP2 increased podocyte apoptosis by mitochondrial injury via ITGA5/FAK phosphorylation pathway in DKD progression, and provided the potential therapeutic strategies for diabetic kidney disease.

Citing Articles

IGFBP2 and IGFBP4 interact to activate complement pathway in diabetic kidney disease.

Liang J, Huang Y, Peng D, Xie Y, Liu Y, Lu X Ren Fail. 2025; 47(1):2440528.

PMID: 39806768 PMC: 11734388. DOI: 10.1080/0886022X.2024.2440528.


Depletion of intrinsic renal macrophages with moderate-to-high expression of , , , , and in regulating podocyte injury in diabetic nephropathy: a single-cell RNA sequencing analysis.

Guo Y, Luo J, Zuo J Transl Androl Urol. 2024; 13(11):2527-2552.

PMID: 39698573 PMC: 11650352. DOI: 10.21037/tau-24-569.


Identification of Spatial Specific Lipid Metabolic Signatures in Long-Standing Diabetic Kidney Disease.

Zhang Y, Piao H, Chen D Metabolites. 2024; 14(11).

PMID: 39590877 PMC: 11596753. DOI: 10.3390/metabo14110641.


Lithium-induced apoptotic cell death is not accompanied by a noticeable inflammatory response in the kidney.

Baranovskaya I, Volk K, Alexander S, Abais-Battad J, Mamenko M Front Physiol. 2024; 15:1399396.

PMID: 39234304 PMC: 11373137. DOI: 10.3389/fphys.2024.1399396.


Podocyte Death in Diabetic Kidney Disease: Potential Molecular Mechanisms and Therapeutic Targets.

Zhong S, Wang N, Zhang C Int J Mol Sci. 2024; 25(16).

PMID: 39201721 PMC: 11354906. DOI: 10.3390/ijms25169035.

References
1.
Kato M, Natarajan R . Epigenetics and epigenomics in diabetic kidney disease and metabolic memory. Nat Rev Nephrol. 2019; 15(6):327-345. PMC: 6889804. DOI: 10.1038/s41581-019-0135-6. View

2.
Cleveland K, Schnellmann R . Pharmacological Targeting of Mitochondria in Diabetic Kidney Disease. Pharmacol Rev. 2023; 75(2):250-262. DOI: 10.1124/pharmrev.122.000560. View

3.
Tuttle K, Agarwal R, Alpers C, Bakris G, Brosius F, Kolkhof P . Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022; 102(2):248-260. DOI: 10.1016/j.kint.2022.05.012. View

4.
Vartak T, Godson C, Brennan E . Therapeutic potential of pro-resolving mediators in diabetic kidney disease. Adv Drug Deliv Rev. 2021; 178:113965. DOI: 10.1016/j.addr.2021.113965. View

5.
Chen Z, Zhu Z, Liang W, Luo Z, Hu J, Feng J . Reduction of anaerobic glycolysis contributes to angiotensin II-induced podocyte injury with foot process effacement. Kidney Int. 2023; 103(4):735-748. DOI: 10.1016/j.kint.2023.01.007. View